Galderma Unveils New Dermatology Data at AAD 2026 — Galderma Group AG

Event summary

Galderma will present 22 abstracts at the AAD 2026 Annual Meeting, including late-breaking data and three oral presentations.
Four presentations focus on Nemluvio (nemolizumab), exploring its efficacy and safety in pediatric patients with moderate-to-severe atopic dermatitis.
Nine presentations cover dermatological skincare, including sensitive skin, acne, eczema-prone, and mature skin.
Five e-posters detail updates from Galderma’s injectable aesthetics portfolio, including Restylane hyaluronic acid products.

The big picture

Galderma's extensive data presentation at AAD 2026 underscores its strategy to dominate the dermatology market through scientific innovation. The company is positioning itself as a full-spectrum provider, addressing diverse skin needs with a portfolio spanning therapeutic dermatology, injectable aesthetics, and skincare. This approach aligns with the growing demand for personalized and effective dermatological solutions, reflecting broader industry trends towards targeted treatments and preventive skincare.

What we're watching

Clinical Validation: How the new data on Nemluvio and AKLIEF will impact their market positioning and adoption rates.
Portfolio Diversification: Whether Galderma can sustain its leadership in dermatology through continuous innovation across therapeutic, skincare, and aesthetics segments.
Regulatory Approvals: The pace at which investigational products like RelabotulinumtoxinA and Restylane Shaype for the jawline gain regulatory approvals.